LAVAL, Quebec / Jun 05, 2025 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 4, 2025. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Daniel N. Chicoine | 5,432,232 | 301,172 | 94.75% | 5.25% |
Anthony E. Dobranowski | 5,455,219 | 278,185 | 95.15% | 4.85% |
John C. London | 5,427,266 | 306,138 | 94.66% | 5.34% |
Deborah Shannon-Trudeau | 5,463,225 | 270,179 | 95.29% | 4.71% |
Serge Verreault | 5,490,982 | 242,422 | 95.77% | 4.23% |
Reappointment of External Auditors
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Ernst & Young LLP reappointed | 6,388,758 | 49,767 | 99.23% | 0.77% |
Approval of the Continuation of Crescita’s Shareholder Rights Plan
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | AGAINST | FOR | AGAINST | |
Shareholder Rights Plan approved | 5,481,368 | 252,036 | 95.60% | 4.40% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
| Last Trade: | C$0.49 |
| Daily Volume: | 0 |
| Market Cap: | C$9.270M |
May 23, 2025 March 18, 2025 November 06, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
